Genmab Feed

Land	Danmark
Lista	Large Cap Copenhagen
Sektor	Hälsovård
Industri	Bioteknik

2020-03-26 21:13:02 Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons -1,47% | 278 MDKK

2020-03-26 20:54:50 Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to the New Member of the Board of Directors and a New Member of Management, and Grant of Restricted Stock Units and Warrants to Employees and a New Member -1,47% | 278 MDKK

2020-03-26 15:26:18 Passing of Genmab A/S’ Annual General Meeting +0,15% | 309 MDKK

2020-03-12 16:33:33 Genmab A/S Provides Update to Annual General Meeting -12,77% | 551 MDKK

2020-03-10 06:09:29 Genmab Announces Appointment of Anthony Mancini to Newly Created Position of Chief Operating Officer -1,11% | 512 MDKK

2020-02-27 10:03:48 Notice to Convene the Annual General Meeting of Genmab A/S -3,10% | 452 MDKK

2020-02-26 18:30:12 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons -3,10% | 452 MDKK

2020-02-25 21:41:10 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons -1,53% | 809 MDKK

2020-02-25 21:28:39 Capital Increase in Genmab as a Result of Employee Warrant Exercise -1,53% | 809 MDKK

2020-02-24 07:32:49 U.S. FDA Filing Acceptance and Priority Review for sBLA, Submitted by Novartis, for Ofatumumab in Relapsing Multiple Sclerosis -0,21% | 436 MDKK

2020-02-21 21:20:41 Genmab Board of Directors Chairman to Step Down -0,21% | 436 MDKK

2020-02-19 17:05:40 Genmab Publishes 2019 Annual Report +3,92% | 1001 MDKK

2020-01-23 10:38:36 Horizon Therapeutics Secures U.S. FDA Approval for Teprotumumab, for the Treatment of Thyroid Eye Disease (TED) -0,77% | 214 MDKK

2020-01-22 12:32:56 Genmab Announces 2019 Net Sales Figures for DARZALEX® (daratumumab) and Achievement of USD 150 Million Sales Milestone in DARZALEX Collaboration with Janssen +2,04% | 448 MDKK

2020-01-20 18:02:40 Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma +0,10% | 159 MDKK

2020-01-06 15:54:05 Genmab to Present at the 38th Annual J.P. Morgan Healthcare Conference -1,73% | 234 MDKK

2020-01-02 22:25:53 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons -2,83% | 322 MDKK

2020-01-02 15:29:53 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons +0,34% | 281 MDKK

2019-12-20 16:19:34 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons -0,41% | 310 MDKK

2019-12-19 16:19:43 Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics +0,48% | 253 MDKK

2019-12-13 12:32:11 CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma -0,37% | 452 MDKK

2019-12-09 14:27:26 Genmab to Hold 2019 R&D Update and ASH Data Review Meeting -2,04% | 406 MDKK

2019-12-05 23:36:36 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 0,00% | 186 MDKK

2019-12-05 23:32:28 Grant of Restricted Stock Units to Board Members, Management and Employees and Grant of Warrants to Employees in Genmab 0,00% | 186 MDKK

2019-12-05 09:49:02 Genmab Achieves USD 100 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen -0,31% | 201 MDKK

2019-11-19 17:14:59 Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma +0,27% | 322 MDKK

2019-11-12 20:08:29 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons +1,11% | 338 MDKK

2019-11-12 20:02:18 Capital Increase in Genmab as a Result of Employee Warrant Exercise +1,11% | 338 MDKK

2019-11-06 17:01:03 Genmab Announces Financial Results for the First Nine Months of 2019 +2,63% | 548 MDKK

2019-11-06 15:19:23 Genmab Announces Data to be Presented at 2019 ASH Annual Meeting +0,31% | 205 MDKK

2019-10-30 21:31:13 David Eatwell to Retire as Chief Financial Officer of Genmab +0,34% | 292 MDKK

2019-10-30 10:31:30 Genmab’s Financial Calendar for 2020 +1,11% | 197 MDKK

2019-10-18 13:09:20 CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma -0,04% | 219 MDKK

2019-10-15 12:47:08 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2019 +3,31% | 327 MDKK

2019-10-11 20:55:12 Grant of Restricted Stock Units and Warrants to Employees in Genmab +0,86% | 149 MDKK

2019-10-01 20:14:42 Capital Increase in Genmab as a Result of Employee Warrant Exercise -5,60% | 444 MDKK

2019-09-26 17:43:42 Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple Myeloma -1,23% | 366 MDKK

2019-09-13 15:40:15 Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma -0,69% | 507 MDKK

2019-09-13 15:04:30 Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS -0,69% | 507 MDKK

2019-09-09 15:07:58 Genmab and Tempus Enter into Strategic Collaboration Agreement -1,28% | 164 MDKK

2019-08-30 07:16:35 Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies +1,84% | 360 MDKK

2019-08-22 07:10:36 Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan +0,18% | 161 MDKK

2019-08-21 23:59:36 Genmab Announces Preliminary Data to be Presented at IASLC 2019 World Conference on Lung Cancer +0,18% | 161 MDKK

2019-08-20 18:47:02 Capital Increase in Genmab as a Result of Employee Warrant Exercise +0,70% | 192 MDKK

2019-08-19 18:47:55 Daratumumab Abstracts Selected for Presentation at 17th International Myeloma Workshop -0,47% | 188 MDKK

2019-08-14 17:00:53 Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance +3,02% | 575 MDKK

2019-07-23 17:28:39 Genmab Announces the Closing of Over-Allotment Option in Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase +1,77% | 597 MDKK

2019-07-22 17:12:52 Genmab Announces the Completion of its Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase -0,33% | 157 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

2020-11-04	Kvartalsrapport 2020-Q3
2020-08-12	Kvartalsrapport 2020-Q2
2020-05-06	Kvartalsrapport 2020-Q1
2020-03-27	Ordinarie utdelning GMAB 0.00 DKK
2020-03-26	Årsstämma 2019
2020-02-19	Bokslutskommuniké 2019
2019-04-01	Ordinarie utdelning GMAB 0.00 DKK
2019-03-29	Årsstämma 2018
2018-11-14	Kvartalsrapport 2018-Q3
2018-08-08	Kvartalsrapport 2018-Q2
2018-05-08	Kvartalsrapport 2018-Q1
2018-04-11	Ordinarie utdelning GMAB 0.00 DKK
2018-04-10	Årsstämma 2017
2018-02-21	Bokslutskommuniké 2017
2017-11-08	Kvartalsrapport 2017-Q3
2017-08-09	Kvartalsrapport 2017-Q2
2017-05-10	Kvartalsrapport 2017-Q1
2017-03-29	Ordinarie utdelning GMAB 0.00 DKK
2017-03-28	Årsstämma 2016
2017-02-22	Bokslutskommuniké 2016
2016-11-10	Kapitalmarknadsdag 2016
2016-11-02	Kvartalsrapport 2016-Q3
2016-08-09	Kvartalsrapport 2016-Q2
2016-05-10	Kvartalsrapport 2016-Q1
2016-03-18	Ordinarie utdelning GMAB 0.00 DKK
2016-03-17	Årsstämma 2015
2016-02-17	Bokslutskommuniké 2015
2015-11-03	Kvartalsrapport 2015-Q3
2015-08-11	Kvartalsrapport 2015-Q2
2015-05-12	Kvartalsrapport 2015-Q1
2015-03-27	Ordinarie utdelning GMAB 0.00 DKK
2015-03-26	Årsstämma 2014
2015-03-02	Bokslutskommuniké 2014
2014-04-10	Ordinarie utdelning GMAB 0.00 DKK
2013-04-18	Ordinarie utdelning GMAB 0.00 DKK
2012-04-26	Ordinarie utdelning GMAB 0.00 DKK
2011-04-07	Ordinarie utdelning
2010-04-22	Ordinarie utdelning

Genmab

Beskrivning

Kalender

Genmab

Beskrivning

Kalender

Språk

Typ

År

Språk

Typ

Ett Mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden